Clinical Trial Update: Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

View source ↗

Summary

This update reports 16-year long-term follow-up data for Betaseron in patients with relapsing-remitting multiple sclerosis, highlighting long-term safety and ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Betaseron (Interferon beta-1b)

Snippet

Sponsor: Bayer | Conditions: Multiple Sclerosis | Status: COMPLETED